Redeye retains its SEK394 Base Case in Lime, leaving notable upside potential given the recent soft ...
Ahead of Enea's Q3 report on 23 October 2025, Redeye is raising its network estimate, buoyed by a ne...
Redeye provides a short comment on the recently announced Q3 sales figure from Scandinavian ChemoTec...
Redeye comments on Nanologica’s press release confirming its first production-evaluation order for i...
Redeye comments on Isofol’s update that the second dose level in its ongoing phase Ib/II study has b...
Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines...
* Byggmästaren proposes extraordinary dividend and share split * Updates dividend policy and reaffir...
* Q3e: 11% organic sales growth, 10% adj. EBITA margin * We lower estimates on continued lack of upf...
* Solid autumn intake * Sonans back on track * Fair value range of NOK 14-25 Solid autumn intake To...
* Q3'25 numbers due on 5 November at 07:45 CET * Adj.
* We forecast 7% EBITA growth in Q3'25 * M&A could add 30-40% to '27e EBITA * We raise our fair valu...
Nettoomsättningen uppgick till 52,2 MSEK (49,2) i det första kvartalet (maj-jul) i Vuxen Groups brut...
Redeye comments on Invisio’s announcement of a 10-year contract with US Coast Guard regarding wirele...
Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities...
Redeye comments on Glenn Paxman’s ownership reduction.
Redeye leaves Addnode’s CMD with a positive impression, as the company’s ambition for growth and mar...
Redeye provides a brief comment on Scibase receiving an initial order valued at approximately SEK8m ...
Redeye provides an update following the company’s Q2 report, which demonstrated significant sequenti...
Redeye updates its estimates for Relais’ recent hybrid bond issue.
Redeye believes the data is solid and in line with previous readouts.